



Harpreet Bajaj MB, BS, MPH, D. ABIM

Brampton #238-2130 North Park Drive, Brampton, Ontario L6S 0C9, Canada

Tel (905) 595-0560

CURRICULUM VITAE

Education, Certification & Licenses

2009	American Board of Internal Medicine (ABIM) certification in Endocrinology, Diabetes and Metabolism	
2007	American Board of Internal Medicine (ABIM) certification	
2007	Ohio Medical Licensure	
2004	BCLS/ACLS certification	
2004	Minnesota Training Certification	
2003	Education Commission for Foreign Medical Graduates (ECFMG) certification	
2002-04	Master of Public Health (MPH), Epidemiology	University of Albany SUNY, NY
1995-99	Bachelor of Medicine and Bachelor of Surgery	Maulana Azad Medical College, University of Delhi, India

Professional Activities

2009- Present	Associate Endocrinologist	LMC Diabetes & Endocrinology
2007-09	Clinical Fellowship in Endocrinology, Diabetes and Metabolism	Cleveland Clinic, Cleveland, OH
2007	GCP Training	CITI Collaborative Institutional Training Initiative
2004-07	Internship and Residency in Internal Medicine	Hennepin County Medical Centre, Minneapolis
2001-02	Junior Residency (Externship) in Emergency Medicine	Government of Delhi Hospitals, New Delhi, India
2000-01	Clinical Internship	Maulana Azad Medical College, Lik Nayak Hospital and Guru Nanak Eye Centre

Achievements, Associations & Specialties

- Intensive Insulin Protocol and Management of Inpatient Hyperglycemia
- Out-patient Management of Diabetes including the use of Insulin Pumps and Continuous Glucose Monitors
- Neck Ultrasound and Fine Needle Aspiration of Thyroid Nodules and Follow-up of Thyroid Cancer
- Interpretation of Bone Densitometry and Treatment of Osteoporosis
- Evaluation and Management of Lipid, Pituitary, Parathyroid, Adrenal and other General Endocrinology Problems

Clinical Trials & Research Activities

2010-2016	R331333-PAI-3027(J&J), H80-CA-GWCE(Lilly), Defend-1(GSK), EMERGE 8(Roche), 28431754-DIA-3012(J&J), 1245.23(BI), 28431754-DIA-3015(J&J), 1245.31(BI), Rewind(Eli Lilly), EFC 1162(Sanofi-aventis), AZ05(AstraZeneca), 1245.48(BI), EFC 12261 (Sanofi-Aventis), TAK-875_306(Takeda), RGN1110(Regeneron), RGN1118(Regeneron), DECLARE 58(AstraZeneca), EFC 12626(Sanofi-Aventis), M11-352 (Abbvie), B1481022(Pfizer), B1481038(Pfizer), INNOVATE(LMC Diabetes&Endocrinology), APD356-G000-401(Eisai), GSN000200(Genkyotex), MK-8835-002(Merck), CREDENCE (Janssen Research), EFC12405 (Sanofi-Aventis), EFC13799 (Sanofi-Aventis), B1481038 (Pfizer), B1481022 (Pfizer), HARMONY 10 (GSK), B1481045 (Pfizer), DERIVE (AstraZeneca), Etc.
2009	Merck 139(Merck Frosst), MB102-029(BMS), TIDE(GSK), 1218.62(BI), EFC10781(Sanofi-aventis)
	Cleveland Clinic, Cleveland, OH(Diabetes, Multiple Sclerosis, Metabolism, Endocrinology)
	Hennepin County Medical Center, Minneapolis, MN(Diabetes)
	University of Minnesota, Minneapolis, MN(Endocrinology)
	New York State Department of Health, NY(Lyme Disease)
	Lok Nayak Hospital, New Delhi, India(Asthma)
	Indian Council of Medical Research (ICMR), Dept. of Regenerative Surgery, India(Neo-organogenesis using stem cells from developed tissue)